Prelude Therapeutics, Inc. (PRLD)
3.26
-0.06
(-1.81%)
USD |
NASDAQ |
Oct 16, 16:00
3.25
-0.01
(-0.31%)
After-Hours: 20:00
Prelude Therapeutics Research and Development Expense (Annual) : 94.30M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 94.30M |
| December 31, 2024 | 118.00M |
| December 31, 2023 | 103.39M |
| December 31, 2022 | 92.89M |
| Date | Value |
|---|---|
| December 31, 2021 | 86.78M |
| December 31, 2020 | 48.18M |
| December 31, 2019 | 24.28M |
| December 31, 2018 | 12.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Q32 Bio, Inc. | 19.16M |
| Intellia Therapeutics, Inc. | 379.09M |
| Twist Bioscience Corp. | 80.28M |
| Beam Therapeutics, Inc. | 409.62M |
| Revolution Medicines, Inc. | 978.68M |